Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list - 2Fundamental Venture The board Apparatuses for Remote Groups
- 3Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- 4No more attempts to free whale stranded off Germany, officials say
- 5Ukraine's naval drones are gunning for Russia's 'shadow fleet.' A security source says a tanker just suffered a critical hit.
- Why haven’t humans been back to the moon in over 50 years?
- The Effect of Online Organizations on Society: Beating the Difficulties
- The Best Internet based Retailers for Style and Frill
- France's Senate backs ban on social media platforms for under-15s
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- Family-Accommodating Snow Sports Experiences
- 2024 Watch Gathering: The Best Watches of the Year
- As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- The Oscars are moving from ABC to YouTube starting in 2029
